Q-Line Biotech Ltd vs Sun Pharmaceutical Industries Ltd

A side-by-side comparison of Q-Line Biotech Ltd (QLINE) and Sun Pharmaceutical Industries Ltd (SUNPHARMA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Sun Pharmaceutical Industries Ltd leads QLINE vs SUNPHARMA on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

14.94
P/E ratio
41.01
2.65
P/B ratio
5.60
0.00%
Dividend yield
0.82%
₹34.24
EPS
₹47.84

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

25.90%
Return on equity
16.00%
22.00%
Return on capital
21.00%
29.00%
EBITDA margin
30.00%
16.37%
Net margin
19.69%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

23.18%
Revenue CAGR (3Y)
10.03%
20.51%
Profit CAGR (3Y)
10.57%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1,316 Cr
Market cap
₹4.67L Cr
₹342 Cr
Revenue
₹58,462 Cr
₹56 Cr
Net profit
₹11,509 Cr
0.75
Debt / equity
0.06
Q-Line Biotech Ltd
  • + ["Company has a good return on equity (ROE) track record: 3 Years ROE 25.2%"]
  • ["Debtor days have increased from 92.7 to 134 days."]
Sun Pharmaceutical Industries Ltd
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 34.1%"]
  • ["The company has delivered a poor sales growth of 11.8% over past five years."]
Q-Line Biotech Ltd full analysis Sun Pharmaceutical Industries Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.